Among them are CRISPR Therapeutics (NASDAQ: CRSP) and Merck (NYSE: MRK), two companies that develop innovative medical ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.

The discovery could pave the way for a groundbreaking RNA-based multi-cancer treatment. Alternative RNA splicing functions ...

Transgenic worm in which the splicing factor UNC-75, marked with the fluorophore mScarlet, reveals its expression throughout the nervous system. The worm was generated using CRISPR-Cas9 gene editing ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

Over the past 15 years, developments in the gene-editing technique known as CRISPR-Cas9 have produced significant new ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

The Chinese scientist who was imprisoned for secretly creating the world’s first genetically-engineered babies has claimed he ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.0, a ...

Bryan Johnson, a businessman who promotes experimental therapies for longevity, was recently featured on 'The Kardashians'.

Cathie Wood’s ARK Invest is taking advantage of the recent dip in Tesla (TSLA) stock by purchasing 9,351 shares through its ARKK ETF (ARKK), ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.0% in ...